Although there are no direct comparative studies that have been published, both teriparatide (PTH [1‐34]) and full‐length PTH (1‐84) appear to be effective for reducing fracture risk in patients with osteoporosis in a range of clinical studies and settings. This evidence concerns the gene PTH and osteoporosis.